An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer
Abstract Dexamethasone has antitumor activity in metastatic castration resistant prostate cancer (mCRPC). We aimed to investigate intravenous liposome‐encapsulated dexamethasone disodium phosphate (liposomal dexamethasone) administration in mCRPC patients. In this exploratory first‐in‐man study, pat...
Guardado en:
Autores principales: | Josephina P. M. Vrouwe, Ingrid M. C. Kamerling, Michiel J. vanEsdonk, Josbert M. Metselaar, Frederik E. Stuurman, Gabri van derPluijm, Jacobus Burggraaf, Susanne Osanto |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7f6f12eb65c74ad0b8cee9f1481033da |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
por: Nikolai A. Ognerubov
Publicado: (2021) -
Advanced Therapeutic Options for Treatment of Metastatic Castration Resistant Prostatic Adenocarcinoma
por: Faiza Naseer, et al.
Publicado: (2021) -
TRACING THE CRIMINAL POLICY ON CASTRATION AND COMMUNITY RESPONSE
por: Mompang L Panggabean
Publicado: (2021) -
Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions
por: Caffo O, et al.
Publicado: (2016) -
A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer
por: Archibald M, et al.
Publicado: (2016)